Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial studies how well personalized neck radiation therapy directed by sentinel lymph node biopsy (SLNB) works in treating patients with oral cavity squamous cell carcinoma (OCSCC). SLNB can be performed as part of standard care for OCSCC. During SLNB, a radiotracer is injected around the tumor. The lymph nodes are then biopsied and tested to see if the tracer injected into the tumor traveled to and is present in the sentinel lymph nodes (SLNs). Results of the SLNB are used to determine whether lymph nodes should be removed in both sides of the neck or just on the same side as the primary tumor. Standard treatment then involves radiation therapy to both sides of the neck, regardless of SLNB results. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Studies have shown only a small number of patients develop a return of the cancer (recurrence) in the opposite side of the neck after radiation therapy. In addition, radiation therapy can negatively impact patient outcomes like saliva production, speech and swallow function, increased risk of radiation induced cancers, and chronic pain. Standard of care SLNBs may be effective in determining whether radiation therapy only needs to be administered to one side of the neck or both sides. This may help spare tissue on the opposite side of the neck from receiving radiation if there is no indication of lymph node involvement there.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony biopsją rak płaskonabłonkowy jamy ustnej.
- •Nowotwór we wczesnym stadium (T1-T4a, N0-2b) bez przerzutów odległych.
- •Pacjent ma dobry ogólny stan zdrowia (nie jest zbyt osłabiony).
- •Wiek powyżej 18 lat.
- •Planowane jest leczenie operacyjne z usunięciem węzłów chłonnych po tej samej stronie co guz i badaniem węzłów wartowniczych.
- •Pacjent wyraża zgodę na udział w badaniu.
✗ Disqualifies
- •Obecność przerzutów odległych.
- •Obecność przerzutów w węzłach chłonnych po przeciwnej stronie szyi.
- •Wcześniejsze leczenie innego nowotworu (z pewnymi wyjątkami).
- •Inny typ nowotworu głowy lub szyi (np. z gardła, krtani).
- •Wcześniejsza chemioterapia lub radioterapia leczonego obecnie nowotworu.
- •Poważne choroby współistniejące, które uniemożliwiają operację.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 31, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University of Michigan Comprehensive Cancer Center
Ann Arbor, United States
Trial contact
Cancer AnswerLine
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.